RESEARCH ARTICLE

Has universal screening with Xpert® MTB/RIF increased the proportion of multidrug-resistant tuberculosis cases diagnosed in a routine operational setting?

Pren Naidoo1*, Rory Dunbar1, Judy Caldwell2, Carl Lombard3, Nulda Beyers1

1 Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa, 2 City Health Directorate, Cape Town, South Africa, 3 Biostatistics Unit, South African Medical Research Council, Cape Town, South Africa

* pnaidoo@icon.co.za

Abstract

Setting

Primary health services in Cape Town, South Africa where the introduction of Xpert® MTB/RIF (Xpert) enabled simultaneous screening for tuberculosis (TB) and drug susceptibility in all presumptive cases.

Study aim

To compare the proportion of TB cases with drug susceptibility tests undertaken and multidrug-resistant tuberculosis (MDR-TB) diagnosed pre-treatment and during the course of 1st line treatment in the previous smear/culture and the newly introduced Xpert-based algorithms.

Methods

TB cases identified in a previous stepped-wedge study of TB yield in five sub-districts over seven one-month time-points prior to, during and after the introduction of the Xpert-based algorithm were analysed. We used a combination of patient identifiers to identify all drug susceptibility tests undertaken from electronic laboratory records. Differences in the proportions of DST undertaken and MDR-TB diagnosed between algorithms were estimated using a binomial regression model.

Results

Pre-treatment, the probability of having a DST undertaken (RR = 1.82)(p<0.001) and being diagnosed with MDR-TB (RR = 1.42)(p<0.001) was higher in the Xpert-based algorithm than in the smear/culture-based algorithm. For cases evaluated during the course of 1st-line TB treatment, there was no significant difference in the proportion with DST undertaken (RR = 1.02)(p = 0.848) or MDR-TB diagnosed (RR = 1.12)(p = 0.678) between algorithms.
Conclusion

Universal screening for drug susceptibility in all presumptive TB cases in the Xpert-based algorithm resulted in a higher overall proportion of MDR-TB cases being diagnosed and is an important strategy in reducing transmission. The previous strategy of only screening new TB cases when 1st line treatment failed did not compensate for cases missed pre-treatment.

Introduction

Multidrug-resistant tuberculosis (MDR-TB), defined as resistance to rifampicin and isoniazid, presents a major global health challenge with an estimated 480,000 incident cases in 2014 [1]. Whilst MDR-TB rates are substantially higher among previously treated cases (20%) than among new cases (3.3%), the latter contribute substantially to the total burden, accounting for an estimated 53% of MDR-TB cases among the pulmonary TB cases notified in 2014 [1]. The high proportion of new TB cases with MDR-TB (primary MDR-TB) suggests significant disease transmission.

Persistent diagnostic gaps due to both inadequate TB case-detection and limited drug susceptibility testing among detected cases contribute to transmission of MDR-TB. Only 6 million of the estimated 9.6 million TB cases in 2014 were detected. Among notified pulmonary TB cases, 300,000 were estimated to have MDR-TB; however just 12% of new and 58% of previously treated cases were tested for drug susceptibility and 123,000 MDR-TB cases were notified globally [1]. Thus it is estimated that 180,000 of the missed MDR-TB cases were among those with undetected TB and 177,000 among detected TB cases not screened for drug susceptibility.

The past reliance on insensitive smear microscopy tests [2–4] as the cornerstone of laboratory diagnosis has contributed to poor TB case-detection, particularly among human immunodeficiency virus (HIV)-infected cases, where sensitivity can be as low as 23% to 50% [5–9]. Limited laboratory capacity for culture and drug susceptibility testing (DST) contributes to poor MDR-TB case-detection: among the 36 high TB or MDR-TB burden countries, only 16 met the benchmark of one laboratory with culture and DST capabilities per five million population in 2010 [10]. In many developing countries these limitations have led to DST being rationed for use among previously treated cases as they are most at risk of MDR-TB [11–13].

The availability of the more sensitive Xpert® MTB/RIF (Xpert)(Cepheid, Sunnyvale, CA, USA) test offers the possibility of improving TB case-detection and simultaneously screening for drug susceptibility. Xpert is a nucleic acid amplification test that detects genetic sequences for Mycobacterium tuberculosis (MTB) complex and simultaneously, the presence of ‘wild type’ or mutations conferring resistance to rifampicin. Xpert has the ability to detect low bacteria loads (limit of detection 131 colony forming units (CFU) per ml) [14] compared to 10,000 CFU per ml for smear [15]) and is particularly useful in diagnosing the smear-negative TB typically found in HIV-infected individuals. Xpert has high sensitivity and specificity for detecting both TB and rifampicin resistance. In a meta-analysis of fifteen studies where Xpert was used as the initial test replacing smear microscopy, pooled sensitivity was 88% (95%CrI 83% to 92%) and specificity was 98% (95% CrI 97% to 99%) for detecting MTB. In eleven of these studies, pooled sensitivity was 94% (95% CrI 87% to 97%) and specificity was 98% (95% CrI 97% to 99%) for rifampicin resistance [16].

While Xpert has the technical capacity to help close MDR-TB diagnostic gaps, very little has been reported on its use in universal drug susceptibility screening under routine operational
conditions. A study in India found that routine, up-front use of Xpert in children under 14-years of age almost tripled the number of Rif-R cases diagnosed (from 22 to 60 among the 8,370 presumptive TB cases screened), than would have been achieved through screening of presumptive DR-TB cases only [17].

Our study compared the proportion of TB cases with DST undertaken and MDR-TB diagnosed pre-treatment in the previous smear/culture-based algorithm and the newly introduced Xpert-based algorithm. Among cases without MDR-TB diagnosed pre-treatment, we compared the proportion with DST undertaken and MDR-TB diagnosed during the course of 1st-line TB treatment. Comparisons were made for new and previously treated TB cases. The study was part of PROVE IT (Policy Relevant Outcomes from Validating Evidence on Impact), an evaluation to assess the impact of new molecular diagnostics on TB and MDR-TB diagnosis and treatment initiation in a routine operational context.

**Methods**

We had previously undertaken and published results of a non-randomised stepped-wedge study to assess TB yield [18]. The current study assessed drug susceptibility screening and MDR-TB diagnosis among the TB cases identified in the previous study. Some details are highlighted here for completeness.

**Setting**

The study was undertaken in Cape Town, South Africa where free TB diagnostic services were provided at 142 primary health care (PHC) facilities in eight health sub-districts. Prior to August 2011, a smear/culture-based diagnostic algorithm was used (Fig 1). All presumptive TB cases were evaluated through two spot sputum specimens, taken 1-hour apart and examined by fluorescence microscopy. In previously treated TB cases, those from congregate settings or with an MDR-TB contact, the second specimen also underwent liquid culture (BACTEC™ MGIT™ 960) and DST with GenoType® MTBDRplus (Hain LifeScience GmbH, Nehren, Germany) line probe assay (LPA).

Between August 2011 and February 2013 an Xpert-based algorithm was phased into the eight health sub-districts with Xpert replacing smear microscopy for all (new and previously treated) presumptive TB cases (Fig 1). The first of two sputum specimens submitted was tested with Xpert; if rifampicin resistance was detected, the second specimen underwent smear, culture and LPA.

In both algorithms, new and previously treated cases in which first line TB treatment regimens failed had specimens submitted for culture and LPA during the course of treatment.

Routine TB Programme data collected during the study period, indicated that the number of notified TB cases declined from 28,644 in 2011 (752/100,000 population) to 25,846 in 2013 (663/100,000 population). HIV co-infection rates were 47% (97% tested) and 44% (98% tested) in respective years. The number of MDR-TB cases notified increased from 1,020 to 1,134, comprising 3.6% and 4.4% of TB cases respectively (Routine TB Programme Data, Cape Town Health Directorate, April 2016).

**Definitions**

_A presumptive TB case_ was defined as an individual with pre-treatment sputum samples submitted for diagnostic purposes.

_A TB case_ was defined as an individual with one or more smears positive and / or culture positive for MTB and / or MTB detected on Xpert. TB cases were categorised as _new_ (an
An MDR-TB case was defined as a TB case with rifampicin resistance on LPA or Xpert, diagnosed either pre-treatment or whilst on 1\textsuperscript{st} line TB treatment. Rifampicin resistance was used as a proxy indicator of MDR-TB.

**Study design, timeframes and population**

The previously published stepped-wedge study assessed TB yield in five sub-districts over seven one-month time-points (T1 to T7) prior to, during and after the introduction of the Xpert-based algorithm [18]. The current study population included all presumptive TB cases with a bacteriological diagnosis of TB in the smear/culture-based algorithm (T1 to T5) and in the Xpert-based algorithm (T3 to T7) (Fig 2).

**Data sources & management**

The National Health Laboratory Services provided TB test data from the electronic laboratory database for 2010–2014. Data included clinic identification, patient clinical folder number, patient demographics, TB category (new, previously treated), test type (smear, culture, LPA or Xpert), diagnostic point (pre-treatment or on 1\textsuperscript{st}-line treatment), test date and result.
Laboratory data for all primary health facilities and all hospitals in Cape Town were imported into Microsoft SQL. We used a combination of patient name, surname, birth date, address and clinical folder number to identify all DSTs undertaken (i.e. a rifampicin result on Xpert / LPA) for the TB cases diagnosed at T1 to T7 and to identify duplicates cases (individuals diagnosed at multiple facilities). DSTs were classified as pre-treatment if recorded as a pre-treatment test or if taken within 7 days of this test. DSTs were classified as taken during 1st line treatment if taken >7 days and up to 9 months after the pre-treatment test. All matches and classification as “pre-treatment” or “treatment” were manually verified.

Data analysis
Cases were allocated to algorithm based on the algorithm in place at the facility at the time-point i.e. we used an intention to treat approach in the analysis. We compared the proportion of TB cases with DST undertaken and MDR-TB diagnosed pre-treatment in the smear/culture-based algorithm and the Xpert-based algorithm. Among cases without MDR-TB diagnosed pre-treatment, we assessed the proportion with DST undertaken and MDR-TB diagnosed during the course of 1st-line TB treatment in both algorithms. Analyses were done for new and for previously treated TB cases.

Descriptive data are presented using proportions and frequencies. Normally distributed continuous outcomes were analysed using the t-test and categorical outcomes using the chi-squared test. A binomial regression model, adjusted for clustering at 60 primary health care sites, was used to estimate differences in the proportions of DST undertaken and MDR-TB cases diagnosed between algorithms and the interaction of age, gender and treatment category variables. We undertook a sub-analysis for new and previously treated cases. We did not
consider a time-effect, as the change in the proportion with DST undertaken over time was inherent to the phased introduction of the Xpert-based algorithm. All analyses were undertaken using STATA 13 (StataCorp).

Ethics statement

The Health Research Ethics Committee at Stellenbosch University (IRB0005239) (N10/09/308) and Ethics Advisory Group at The International Union Against Tuberculosis and Lung Disease (59/10) approved the study. A waiver of informed consent was granted for the use of routine data. The City Health Directorate, Western Cape Health Department and National Health Laboratory Service granted permission to use routine health data. Data sharing is possible following approval by these authorities.

Results

A total of 5,019 TB cases were diagnosed in the smear/culture-based algorithm and 5,444 in the Xpert-based algorithm. Among these, 7 and 3 cases were excluded from respective algorithms as they were known MDR/XDR-TB cases (with tests incorrectly reported as pre-treatment) and 97 and 72 from respective algorithms were merged with corresponding records as they belonged to individuals diagnosed at multiple facilities. The remaining 4,915 TB cases in the smear/culture group and 5,369 in the Xpert group were included in the analysis.

Characteristics of TB cases and those with DST undertaken by algorithm

There were no significant differences in age, gender or TB category (new or previously treated) between TB cases in the smear/culture and Xpert groups (Table 1). For those with DST

| Characteristics of TB cases evaluated by algorithm. | Smear/culture-based algorithm | Xpert-based algorithm | p-value |
|---|---|---|---|
| TB cases | Total | 4,915 | 5,369 | - |
| Mean age (Years) [SD] | 35 [13] | 35 [12] | 0.905 |
| Number male (%) | 2,702 (55) | 2,995 (56) | 0.811 |
| Number female (%) | 2,086 (42) | 2,290 (43) | |
| Number new cases (%) | 2,990 (61) | 3,322 (62) | 0.309 |
| DST undertaken pre-treatment | Number previously treated cases (%) | 1,490 (30) | 1,583 (29) | |
| Mean age (Years) [SD] | 36 [11] | 35 [12] | 0.043 |
| Number male (%) | 1,165 (56) | 2,396 (57) | 0.784 |
| Number female (%) | 879 (42) | 1,781 (42) | |
| Number new cases (%) | 946 (45) | 2,733 (65) | <0.001 |
| DST undertaken for cases on 1st line TB treatment | Number previously treated cases (%) | 1015 (48) | 1,253 (30) | |
| Mean age (Years) [SD] | 35 [12] | 37 [11] | 0.135 |
| Number male (%) | 122 (55) | 164 (66) | 0.013 |
| Number female (%) | 96 (43) | 80 (32) | |
| Number new cases (%) | 102 (46) | 122 (49) | 0.469 |
| Number previously treated cases (%) | 101 (46) | 105 (43) | |

doi:10.1371/journal.pone.0172143.t001
undertaken pre-treatment, cases in the smear/culture group were slightly older and contained a lower proportion of new cases (45% compared to 65% in the Xpert group). Among those with DST undertaken on treatment, the smear/culture group contained a higher proportion of females (43% compared to 32% in the Xpert group).

**Proportion of TB cases with drug susceptibility testing and MDR-TB diagnosed by algorithm**

DSTs were undertaken pre-treatment for 42.7% of TB cases in the smear/culture group compared to 78.9% in the Xpert group and 5.5% and 7.7% of TB cases in respective groups had MDR-TB diagnosed (Table 2). Among cases not initially diagnosed with MDR-TB, 4.8% and 5.0% in respective groups had DST undertaken during the course of 1st-line TB treatment and 0.6% and 0.9% respectively were diagnosed with MDR-TB. In these MDR-TB cases, a lower proportion of cases had received an initial pre-treatment DST in the smear/culture group (5/28) than in the Xpert group (21/43) \( p = 0.008 \).

Among new TB cases, DSTs were undertaken pre-treatment for 31.6% of TB cases in the smear/culture group compared to 82.3% in the Xpert group and 2.7% and 5.5% of new TB cases in respective groups had MDR-TB. Among new TB cases not initially diagnosed with MDR-TB, similar proportions had DST undertaken (3.5% and 3.9% respectively) and were diagnosed with MDR-TB (0.3% and 0.5% respectively) during the course of 1st-line TB treatment.

Among previously treated TB cases, DSTs were undertaken pre-treatment for 68.1% of TB cases in the smear/culture group compared to 79.2% in the Xpert group and 10.6% and 11.5% of previously treated TB cases in respective groups had MDR-TB diagnosed. Among previously treated TB cases not initially diagnosed with MDR-TB, similar proportions had DST undertaken (7.6% and 7.5% respectively) and were diagnosed with MDR-TB (1.4% in both algorithms) during the course of 1st-line TB treatment.

**Comparing TB cases with DST undertaken pre-treatment and MDR-TB diagnosed by algorithm**

The probability of having a DST undertaken pre-treatment was 1.82 times higher in the Xpert group than in the smear/culture group \( p < 0.001 \) (Table 3). Previously treated TB cases were more likely to have DST undertaken \( \text{RR} = 1.09, p = 0.001 \) than new cases.

**Table 2. Drug susceptibility testing and MDR-TB cases diagnosed by TB diagnostic algorithm**. Data is not shown for cases with TB category “unknown” (435 cases (8.9%) in smear/culture group and 464 (8.6%) in Xpert group) but can be calculated based on the numbers shown. DST (drug susceptibility tests) and MDR-TB (multidrug-resistant tuberculosis) pre-treatment are expressed as a percentage of TB cases. DST and MDR-TB on 1st line TB treatment are expressed as a percentage of TB cases not initially diagnosed with MDR-TB. Abbreviations: TB—tuberculosis; MDR-TB—multidrug-resistant tuberculosis.

|                     | Smear/culture-based algorithm Number of cases (%) | Xpert-based algorithm Number of cases (%) |
|---------------------|-------------------------------------------------|------------------------------------------|
|                     | All TB cases | New TB cases | Previously treated cases | All TB cases | New TB cases | Previously treated cases |
| Number of TB cases  | 4915         | 2990         | 1490                      | 5369         | 3322         | 1583                     |
| DST undertaken pre-treatment | 2099 (42.7) | 946 (31.6) | 1015 (68.1)              | 4235 (78.9) | 2733 (82.3) | 1253 (79.2)              |
| MDR-TB diagnosed pre-treatment | 269 (5.5)   | 82 (2.7)    | 158 (10.6)               | 415 (7.7)   | 184 (5.5)   | 182 (11.5)               |
| DST undertaken on 1st line TB treatment | 221 (4.8)   | 102 (3.5)   | 101 (7.6)                | 247 (5.0)   | 122 (3.9)   | 105 (7.5)                |
| MDR-TB diagnosed on 1st line TB treatment | 28 (0.6)    | 9 (0.3)     | 18 (1.4)                 | 43 (0.9)    | 15 (0.5)    | 20 (1.4)                 |
| Total MDR-TB diagnosed | 297 (6.0)   | 91 (3.0)    | 176 (11.8)               | 458 (8.5)   | 199 (6.0)   | 202 (12.8)               |

doi:10.1371/journal.pone.0172143.t002
The likelihood of being diagnosed with MDR-TB was 1.42 times higher in the Xpert group than in the smear/culture group (p < 0.001). Previously treated cases were more likely to be diagnosed with MDR-TB pre-treatment than new cases (RR = 2.67, p < 0.001).

Among new TB cases, the likelihood of a DST being undertaken pre-treatment was 2.64 times higher (p < 0.001) and of MDR-TB being diagnosed was 2.09 times higher (p < 0.001) in the Xpert group than in the smear/culture group. Among previously treated TB cases, the likelihood of a DST being undertaken pre-treatment was 1.15 times higher in the Xpert group than in the smear/culture group (p = 0.376); however, the risk of being diagnosed with MDR-TB was not increased (RR = 1.09, p = 0.376).

Comparing cases with DST undertaken whilst on 1st line TB treatment by algorithm and MDR-TB diagnosed

Among TB cases not initially diagnosed with MDR-TB, there was no significant difference in the proportion with DST undertaken during the course of 1st-line TB treatment in the Xpert
group (RR = 1.02; p = 0.848) compared to with smear/culture group (Table 4). Females were less likely to be screened for drug susceptibility than males (RR = 0.77; p = 0.015). Previously treated TB cases were more likely to be screened for drug susceptibility than new cases (RR = 2.02, p < 0.001).

The likelihood of being diagnosed with MDR-TB during the course of 1st-line TB treatment was similar in the Xpert (RR = 1.12; p = 0.678) and smear/culture groups. Previously treated TB cases were 3.96 times more likely to be diagnosed with MDR-TB than new cases (p < 0.001).

**Discussion**

Previously treated TB cases are at significantly higher risk of MDR-TB than new cases [11–13]. Many countries including South Africa have historically rationed the use of DST in favour of these cases. Thus, in the previous smear/culture-based algorithm drug-susceptibility testing in presumptive TB cases was limited to those at high risk of MDR-TB, namely those who were previously treated for TB, with MDR-TB contacts or from congregate settings. The assumption was that the smaller proportion of new TB cases with drug resistance would be detected during the course of 1st-line treatment.

In comparison, the Xpert-based algorithm required all presumptive TB cases to be screened with Xpert. As expected, our study found that a higher proportion TB cases were screened for drug susceptibility pre-treatment in the Xpert-based algorithm (78.9%) compared to in the smear/culture-based algorithm (42.7%). Overall, TB cases were 82% more likely to be screened for drug susceptibility and 42% more likely to be diagnosed with MDR-TB pre-treatment in the Xpert-based algorithm than in the smear/culture-based algorithm. These differences were accentuated among new cases (RR = 2.64 for DST and RR = 2.09 for MDR-TB). Although previously treated cases were also more likely to have a DST in the Xpert-based algorithm (RR = 1.15) there was no significant increase in the likelihood of an MDR-TB diagnosis.

Interestingly, similar proportions of cases were screened for drug susceptibility (RR = 1.02; p = 0.848) and identified with MDR-TB (R = 1.12; p = 0.678) during the course of 1st-line TB treatment in the Xpert-based algorithm compared to in the smear/culture-based algorithm. The assumption that new cases with MDR-TB that were initially missed in the smear/culture-based algorithm would be picked up during the course of treatment appears not to hold true. We speculate that there may have been cases that died or were lost to follow-up before the opportunity to screen them for drug resistance presented.
It is notable that women were less likely to have a DST undertaken during the course of 1st line TB treatment than men. It is difficult to know whether this is due to reduced perceptions of risk (perhaps due to better adherence to treatment) or to women receiving a poorer quality of service [19–23].

There were over double the number of new compared to previously treated TB cases in the Xpert-based algorithm. Although the proportion of MDR-TB is higher among previously treated TB cases than among new cases, the large number of new TB cases means that they contributed almost equally to the number of MDR-TB cases diagnosed pre-treatment with Xpert. Failure to identify these cases early has serious consequences. It contributes to ongoing transmission of MDR-TB which is substantially more expensive [24] and difficult to treat successfully [25]. Inappropriate treatment leads to amplification of drug resistance [26,27] and exacerbates costs [24] and poor treatment outcomes [25]. The direct impact on patients of failing to identify MDR-TB pre-treatment should not be underestimated. Interviews undertaken as part of PROVE IT illustrated the physical and emotional suffering endured by patients when 1st line TB regimens failed, how socio-economic difficulties were compounded and the devastating impact on families, particularly when children were infected [28,29].

Strengths and limitations

The strength of an operational evaluation is that it reflects the reality of routine practice, including the impact of inconsistent implementation of diagnostic procedures. The evaluation was undertaken in the early phase of Xpert implementation which may have contributed to sub-optimal implementation of this algorithm, as not all presumptive TB cases received an Xpert test as required, resulting in an under-estimation of effect. However, even in the well-entrenched smear/culture-based algorithm, fewer previously treated cases had DST undertaken as required than in the newly introduced Xpert-based algorithm.

A major strength of the study was that we were had retrospective data that enabled us to assess DST undertaken during the course of treatment. This allowed us to assess whether limited initial DST and MDR-TB diagnosis was compensated by screening and diagnosis during the course of 1st-line TB treatment; we found this not to be the case.

The completeness of routine data, with missing age (<5%), gender (<3%) and treatment category (<9%) variables in both groups is a limitation but is unlikely to have influenced overall findings at these levels. We were unable to analyse the interaction of HIV as this data was not available in the electronic laboratory dataset.

Our case definitions did not take account of discordant Rif-R results. Among the 223 cases with Rif-R on Xpert, 24 did not have confirmatory LPA and 12 had a discordant first LPA result (the majority of these did not have further tests undertaken). This may have resulted in an over-estimation of the proportion of true positive Rif-R cases in the Xpert-based algorithm. An intention to treat approach was adopted with the analysis based on the algorithm in place at the facility and not the tests undertaken. During the transition between algorithms, some contamination occurred with facilities in the smear/culture based algorithm testing patients via Xpert, resulting in a slight over-estimation of pre-treatment DST undertaken (additional 102 cases) and MDR-TB cases diagnosed (additional 3 cases).

Implications for policy and practice

Overall 8.5% of TB cases were detected with MDR-TB in the Xpert-based algorithm compared to 6% in the smear/culture-based algorithm. If one applies these proportions to the approximately 15,000 bacteriologically diagnosed PTB cases in all eight sub-districts in Cape Town
annually, it translates to a substantial programmatic effect—an additional 375 MDR-TB cases diagnosed annually.

A recent national DR-TB prevalence survey in South Africa reported high rates of rifampicin resistance—3.4% among new cases and 7.1% among previously treated cases in 2012–2014 [30], confirming high rates of transmission and a substantial national burden. The use of Xpert MTB/RIF as a screening tool for all presumptive TB cases is important in detecting these cases and reducing transmission, but comes at a high cost. A laboratory costing study undertaken as part of PROVE-IT reported an incremental cost-effectiveness ratio of $6,274 per MDR-TB case identified in the Xpert-based algorithm [31].

In addition to identifying patients with MDR-TB, reduced transmission will also be influenced by the proportion who initiate treatment, treatment delay and treatment success. Routine data from South Africa shows that only 62% of detected MDR-TB cases (11,538/18,734) initiated treatment in 2014 [1]. Whilst studies have reported reductions in delay from MDR-TB diagnosis to treatment [32,33], pre-diagnostic delays are unknown. Two systematic reviews in TB patients reported average (mean or median) time delays from symptom onset to first health care visit of 5–162 days [34] and 7–69 days [35] respectively. These may well be longer for MDR-TB patients. Treatment success rates are dismal: MDR-TB treatment success rates of 39% were reported for cases registered nationally in 2009–2011 [25]. Decentralised treatment models also reported low success rates: 52% in a study in the Western Cape [36] and in KwaZulu Natal, 54% from centralised treatment compared to 58% from decentralised treatment [37]. Health system improvements, appropriate support for patients and improved regimens are required to improve treatment initiation, adherence and outcomes in order to help reduce MDR-TB transmission.

**Conclusion**

Universal drug susceptibility testing (i.e. among all presumptive TB cases) in the Xpert-based algorithm detected a significantly higher proportion of MDR-TB cases than the rationed approach used in the smear/culture-based algorithm. The previous strategy of only screening new TB cases when 1st line treatment failed did not compensate for cases missed pre-treatment. However, universal screening with Xpert is an expensive strategy—in order to justify this expenditure, patient and diagnostic delays must be decreased; health services strengthened and new treatment regimens introduced to improve MDR-TB treatment initiation and outcomes. The cost of Xpert needs to be reduced to ensure sustainability.

**Acknowledgments**

The assistance of the National Health Laboratory Services, Cape Town Health Directorate and Western Cape Provincial Department of Health is acknowledged. We are grateful to the TREAT-TB team for their support.

**Author Contributions**

**Conceptualization:** PN RD JC CL NB.

**Data curation:** RD PN.

**Formal analysis:** PN RD CL.

**Funding acquisition:** PN NB.

**Investigation:** PN RD.
Methodology: PN RD JC CL NB.

Project administration: PN.

Resources: PN RD.

Software: RD.

Supervision: PN NB.

Validation: PN RD.

Visualization: PN RD.

Writing – original draft: PN.

Writing – review & editing: PN RD JC CL NB.

References

1. World Health Organisation. Global Tuberculosis Report 2015. 2015.
2. Mase SR, Ramsay A, Ng V, Henry M, Hopewell PC, Cunningham J, et al. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis. 2007; 11(5):485–95. PMID: 17439669
3. Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, Cunningham J, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006; 6(9):S70–81. doi: 10.1016/S1473-3099(06)70578-3 PMID: 16931408
4. Steingart KR, Ng V, Henry M, Hopewell PC, Ramsay A, Cunningham J, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006; 6(10):664–74. doi: 10.1016/S1473-3099(06)70602-8 PMID: 17008175
5. Balcha TT, Sturegård E, Winqvist N, Skogmar S, Reepalu A, Jemal ZH, et al. Intensified tuberculosis case-finding in HIV-positive adults managed at Ethiopian health centers: diagnostic yield of Xpert MTB/RIF compared with smear microscopy and liquid culture. PLoS One. 2014; 9(1):e85478. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3899028&tool=pmcentrez&rendertype=abstract. [cited 2014 Aug 21] doi: 10.1371/journal.pone.0085478 PMID: 24465572
6. Lawn SD, Brooks S V, Kranzer K, Nicol MP, Whitelaw A, Vogt M, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med. 2011; 8(7):e1001067. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3144215&tool=pmcentrez&rendertype=abstract. [cited 2014 Aug 13] doi: 10.1371/journal.pmed.1001067 PMID: 21818180
7. Cattamanchi A, Dowdy DW, Davis JL, Worodria W, Yoo S, Joloba M, et al. Sensitivity of direct versus concentrated sputum smear microscopy in HIV-infected patients suspected of having pulmonary tuberculosis. BMC Infect Dis. 2009; 9:53. doi: 10.1186/1471-2334-9-53 PMID: 19419537
8. Theron G, Peter J, van Zyl-Smit R, Mishra H, Streicher E, Murray S, et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med. 2011; 184(1):132–40. doi: 10.1164/rcrm.201101-0056OC PMID: 21493734
9. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2013; 383(9915):424–35. doi: 10.1016/S0140-6736(13)62073-5 PMID: 24176144
10. World Health Organisation. Global Tuberculosis Report 2011. 2011.
11. Caminero JA. Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis. 2010; 14(4):382–90. PMID: 20202293
12. Rifat M, Milton AH, Hall J, Oldmeadow C, Islam MA, Husain A, et al. Development of multidrug resistant tuberculosis in Bangladesh: A case-control study on risk factors. PLoS One. 2014; 9(8):2–8. [cited 8 Sept 2016]
13. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax. 2006; 61(2):156–63. doi: 10.1136/thx.2005.045963 PMID: 16254056
14. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol. 2010; 48(1):229–37. doi: 10.1128/JCM.01463-09 PMID: 19864480
15. Caulfield AJ, Wengenack NL. Diagnosis of active tuberculosis disease: From microscopy to molecular techniques. J Clin Tuberc Other Mycobact Dis. 2016; 4:33–43.

16. Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M D N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults (Review). Cochrane Collaboration. 2013 [cited 2013 Aug 11]. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009593.pub2/pdf/standard

17. Raizada N, Sachdeva KS, Swaminathan S, Kulsange S, Khaparde SD, Nair SA, et al. Piloting upfront Xpert MTB/RIF testing on various specimens under programmatic conditions for diagnosis of TB & DR-TB in paediatric population. PLoS One. 2015; 10(10):1–15. Available from: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0140375 [cited 27 Jan 2017]

18. Naidoo P, Dunbar R, Lombard C, du Toit E, Caldwell J, Detjen A, et al. Comparing Tuberculosis Diagnostic Yield in Smeared/Culture and Xpert® MTB/RIF-Based Algorithms Using a Non-Randomised Stepped-Wedge Design. PLoS One [Internet]. 2016; 11(3):e0150487. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26930400

19. Neyrolles O, Quintana-Murci L. Sexual inequality in tuberculosis. PLoS Med. 2009; 6(12). e1000199. [cited 07 September 2016] doi: 10.1371/journal.pmed.1000199 PMID: 20027210

20. Hof Susan V, Camilo A Najilis EB and MS. A systematic review on the role of gender in tuberculosis control. 2010[September]. http://www.tbcare1.org/publications/toolbox/tools/access/Role_of_Gender_in_TB_Control.pdf

21. Feng JY, Huang SF, Ting WY, Chen YC, Lin YY, Huang RM, et al. Gender differences in treatment outcomes of tuberculosis patients in Taiwan: A prospective observational study. Clin Microbiol Infect. 2012; 18(9). E331–E337 doi: 10.1111/j.1469-0691.2012.03931.x PMID: 22734962

22. Begum V, De Colombani P, Das Gupta S, Salim AH, Hussain H, Pietroni M, et al. Tuberculosis and patient gender in Bangladesh: Sex differences in diagnosis and treatment outcome. Int J Tuberc Lung Dis. 2001; 5(7):604–10. PMID: 11467366

23. Smith A, Burger R, Claassens M, Ayles H, Godfrey-Faussett P, Beyers N. Health care workers’ gender bias in testing could contribute to missed tuberculosis among women in South Africa. Int J Tuberc Lung Dis. 2016; 20(3):350–6. doi: 10.5588/ijtld.15.0312 PMID: 27046716

24. Pooran A, Pieterse E, Davids M, Theron G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS One. 2013; 8(1):e54587. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3548831&tool=pmcentrez&rendertype=abstract [cited 2014 Jul 11] doi: 10.1371/journal.pone.0054587 PMID: 23349933

25. Schnippel K, Shearer K, Evans D, Berhanu R, Dlamini S, Ndjeka N. International Journal of Infectious Diseases Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: A cohort analysis of the national case regist. Int J Infect Dis.2015; 39:89–94. doi: 10.1016/j.ijtld.2015.09.002 PMID: 26358856

26. Furin JJ, Becerra MC, Shin SS, Kim JY, Bayona J, Farmer PE. Effect of administering short-course, standardized regimens in individuals infected with drug-resistant Mycobacterium tuberculosis strains. Eur J Clin Microbiol Infect Dis. 2000; 19(2):132–6. PMID: 10746502

27. Seddon JA, Warren RM, Enarson DA, Beyers N, Schaaf HS. Resistance Amplification within Families. Emerging Infect Dis. 2012; 18(8). http://dx.doi.org/10.3201/eid1808.111650

28. Naidoo P, van Niekerk M, du Toit E, Beyers N, Leon N. Pathways to multidrug-resistant tuberculosis. Emerg Infect Dis. 2001; 5(7):604–10. PMID: 11467366

29. du Toit E, Squire SB, Lombard C, Caldwell J, Detjen A, et al. A Comparison of Multidrug-Resistant Tuberculosis Treatment Commencement Times in MDRTBPlus Line Probe Assay and Xpert® MTB/RIF-Based Algorithms in a Routine Operational Setting in Cape Town. PLoS One. 2014; 9(7):e103328. [cited 2014 Aug 1] doi: 10.1371/journal.pone.0103328 PMID: 25079599

30. National Institute for Communicable Diseases, South Africa. South African Tuberculosis Drug Resistance Survey 2012–14. 2016

31. Naidoo P, Dunbar R, Toit E, Van Niekerk M, Squire SB, Beyers N, et al. Comparing laboratory costs of smear culture and Xpert W MTB / RIF-based tuberculosis diagnostic algorithms. Int J Tuberc Lung Dis. 2016; 20:1377–85. doi: 10.5588/ijtld.16.0081 PMID: 27729051

32. Naidoo P, du Toit E, Dunbar R, Lombard C, Caldwell J, Detjen A, et al. A Comparison of Multidrug-Resistant Tuberculosis Treatment Commencement Times in MDRTBPlus Line Probe Assay and Xpert® MTB/RIF-Based Algorithms in a Routine Operational Setting in Cape Town. PLoS One. 2014; 9(7):e103328. [cited 2014 Aug 1] doi: 10.1371/journal.pone.0103328 PMID: 25079599

33. Cox HS, Daniels JF, Muller O, Nicol MP, Cox V, Van Cutsem G, et al. Impact of Decentralized Care and the Xpert MTB / RIF Test on Rifampicin-Resistant Tuberculosis Treatment Initiation in Khayelitsha, South Africa: A Pragmatic Randomised Trial. PLoS Med 11(11): e1001760.
34. Sreeramareddy CT, Panduru K V, Menten J, Van den Ende J. Time delays in diagnosis of pulmonary tuberculosis: a systematic review of literature. BMC Infectious Diseases 2009, 9:91. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2702369&tool=pmcentrez&rendertype=abstract doi: 10.1186/1471-2334-9-91 PMID: 19519917

35. Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health. 2008; 8:15. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2265684&tool=pmcentrez&rendertype [cited 2014 Jan 24] doi: 10.1186/1471-2458-8-15 PMID: 18194573

36. Cox H, Hughes J, Daniels J, Azevedo V, McDermid C, Poolman M, et al. Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. Int J Tuberc Lung Dis. 2014; 18(4):441–8. doi: 10.5588/ijtld.13.0742 PMID: 24670700

37. Loveday M, Wallengren K, Voce a, Margot B, Reddy T, Master I, et al. Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis. 2012; 16(2):209–15. doi: 10.5588/ijtld.11.0401 PMID: 22236922